Press releases

Isconova AB has received an approval from the Hungarian regulatory authorities GYEMSZI to initiate a clinical phase I trial with a rabies vaccine in humans.

Genocea Biosciences has fully enrolled the ongoing phase I/IIa clinical study of their investigational therapeutic vaccine candidate (GEN-003) for herpes simplex virus type 2 (HSV-2) with Isconova’s Matrix-M adjuvant. Genocea expects to report preliminary data in the second half of 2013.

Genocea Biosciences has published preclinical results for their investigational therapeutic herpes simplex type 2 (HSV-2) vaccine candidate GEN-003. The results, published in Journal of Virology, show that vaccination with GEN-003 including Isconova AB’s Matrix-M adjuvant induces protection against recurrent disease in preclinical models.

Pre-clinical data on Isconova’s proprietary adjuvant Matrix-M demonstrate immune-enhancing properties and potentiated immune responses to an influenza vaccine. The data was published in the renowned scientific journal Vaccine in its February 4 issue.

The Fraunhofer USA Center for Molecular Biotechnology, Newark, USA has issued a press release describing that they will receive up to 9,9 Million US dollars to develop an Anthrax vaccine containing Matrix-M™, the proprietary adjuvant from Isconova. The project has been funded with Federal Funds from the NIH (National Institutes of Health).

Bo Håkansson has acquired shares in Isconova AB. His holding after acquisition amounts to 1,399,628 shares, corresponding to 11.2 percent of the shares and votes fully diluted. The acquisition was carried out through the recently completed and guaranteed new share issue and subsequent purchase of shares, thus making Bo Håkansson the second largest shareholder in Isconova.

Isconova AB, a leading international vaccine adjuvant company will be presenting at World Vaccine Congress in Lyon, France on October 18th.

Isconova AB, a leading international vaccine adjuvant company will be presenting at Influenza Vaccines for the World Conference in Valencia, Spain on October 12th.

Isconova AB’s partner The Jenner Institute at Oxford University (U.K.) has received approval from Medicines and Healthcare products Regulatory Agency (MHRA) in the UK to initiate a phase I study with a malaria vaccine candidate, containing Isconova’s proprietary adjuvant Matrix-M™.

The Extraordinary General Meeting (EGM) of Isconova AB (publ), corp. reg. no. 556549-4019, will be held at 4:00 p.m. on Monday, October 1, 2012 at the company’s premises at Kungsgatan 109 in Uppsala, Sweden.

Isconova AB's U.S. partner Genocea Biosciences has received approval from the Food and Drug Administration (FDA) to initiate a Phase I/IIa study. The study relates to a therapeutic vaccine candidate (GEN 003) to treat Herpes Simplex Virus-2 (HSV-2). The vaccine candidate includes two novel protein antigens combined with Isconova’s proprietary adjuvant Matrix-M™.

Isconova has concluded a partnership agreement with Virbac – the world's leading pharmaceutical companies in veterinary medicine. In a first step, Isconova’s adjuvant Matrix-M™ will be used by Virbac for the development and improvement of vaccines for the global veterinary market. The first products based on Matrix-M™ are vaccines for dogs against certain infectious diseases. Isconova will receive development milestone payments, and royalties based on Virbac’s future sales of these vaccines.

Isconova AB, a leading international vaccine adjuvant company, announces first results from a successful phase I study using the Company’s proprietary vaccine adjuvant, Matrix M™. This study forms part of the clinical proof of concept for Matrix M™ and its utility in improving the clinical efficacy of seasonal influenza vaccines in the elderly. Both the primary as well as secondary clinical endpoints were reached.

Isconova AB, a leading international vaccine adjuvant company, announces that current member of the Board and former acting CEO of Isconova, Russell G. Greig, has been appointed Chairman of Isconova AB. He succeeds Ulf Tossman who will remain as an ordinary member of the Board.

Isconova AB, a leading international vaccine adjuvant company, is pleased to announce the appointment of Sven Andréasson as CEO of the Company, effective 1st March 2012. Sven, currently CEO of Beta-Cell NV in Brussels, succeeds Russell G. Greig, who has been acting CEO since August 2011.

Isconova AB announces that its partner, VetBioChem, has launched two new dog and cat rabies vaccines on the Russian market. Both vaccines contain Isconova’s Matrix-M™ Vet adjuvant, and Isconova will receive production revenues and royalties on sales.

Isconova AB, a leading international vaccine adjuvant company, is pleased to note that the scientific journal Vaccine has published online, the first article presenting data from the human PanFluVac trial. The phase I clinical study evaluated the safety and the immunogenicity of an avian flu vaccine adjuvanted with Matrix M™. Isconovas Matrix M™ showed excellent results in the study.

Isconova AB, a leading international vaccine adjuvant company and Genocea Biosciences, Inc., a vaccine discovery and development company pioneering a new class of T cell‐based vaccines, today announced the expansion of their collaboration granting Genocea the right to use Isconova’s Matrix M™ in vaccines targeting two additional diseases.

Isconova has appointed Russell Greig, currently a member of its board, as acting CEO for the company. He will assume this position on October 1st 2011 to replace Lena Söderström, who will leave Isconova at the end of September. The recruitment process to find a permanent CEO has been initiated.

Isconova has entered into a new license agreement with Crucell N.V.. The agreement grants Crucell the license to use Isconova’s adjuvant Matrix M™ in HIV and malaria vaccines. An existing agreement between Isconova and Crucell already granted Crucell the right to use Isconova’s Matrix M™ in influenza vaccines.

Isconova moves forward with the clinical Phase I study of seasonal influenza by initiating vaccinations of the first study participants. A total of 110 healthy volunteers will take part in the study, scheduled to be reported during the first quarter of 2012. The study is a result of Isconova’s increased focus on human vaccines.

Isconova AB held its Annual General Meeting on May 5th in Uppsala. The Parent Company and Group’s income statements and balance sheets for the fiscal year 2010 were approved at the meeting. The Board of Directors and CEO were granted a discharge from liability for the fiscal year 2010.

Isconova acquires the assets of Nordic Vaccine A/S, a Danish research and development company specialised in adjuvants and drug delivery development. The acquisition will significantly strengthen Isconova’s patent position within vaccine systems and adjuvant technology.

The Annual General Meeting (AGM) of Isconova AB (publ), corp. reg. no. 556549-4019, will be held at 5.00 p.m. on Thursday, May 5, 2011 at the company’s premises on Kungsgatan 109 in Uppsala, Sweden.

Based on positive results from the clinical Phase I study with Matrix M™ when vaccinating against avian influenza, which was performed in 2009, Isconova has decided to independently conduct a clinical Phase I study of seasonal influenza. The study is a result of Isconova’s increased commitment to human vaccines and is scheduled to start in May 2011.

Isconova’s partner NPO Narvac (”Narvac”) has submitted a registration application in Russia for Matrix M™ based rabies vaccines for dog and cat. Launch of the products on the Russian market is expected end of 2011 after which Isconova independently will prepare for launch on additional markets.

Isconova and Norwegian PHARMAQ AS (“PHARMAQ”) will extend their cooperation after receiving positive notice from Eurostars™ (“Eurostars”) regarding funding of an extensive development project for new, effective, salmon vaccines. Eurostars will finance a large part of Isconova’s and PHARMAQ’s development costs in developing a new, innovative generation of fish vaccines.

Isconova has been selected as a partner in a new EU project. One of the objectives for the project – the so-called WINGS project – is to develop a new vaccine against the viral disease West Nile Fever. Isconova will lead part of the project aimed at optimizing a protein-based vaccine using Isconova’s adjuvant Matrix M™, as well as contribute with its expertise in adjuvants.

This press release may not be released, published or distributed in the U.S., Canada, Australia, Japan or any other country if it requires any additional prospectus prepared or registration or other measures in addition to those required under Swedish law.

Isconova has entered a global, strategic collaboration with Jenner Institute – one of the leading vaccine institutes in the world. The aim of the collaboration is to develop vaccines, including a malaria vaccine, by using Isconova’s knowledge and products.

Isconova initiates collaboration with NPO Narvac (”Narvac”) – one of Russia’s leading companies within veterinary medicine. Initially, the aim is to develop a rabies vaccine for dog and cat for the Russian market. Isconova will own all clinical data and in addition own the commercial rights for the vaccines throughout the rest of the world, except for China, where Isconova and Narvac will co-operate through a joint venture.

Isconova’s adjuvant Matrix M™ has been selected by the Swiss biotech-company Evolva Holding SA (“Evolva”) as one of three immune-stimulating substances further studies (pre-IND). The properties of the product have made it appropriate for use against bio-terrorism.

Pharmaceutical company Isconova has recruited Erik Bergman as CFO. Most recently Erik comes from Orexo’s subsidiary Kibion where he has been CEO since 2009. The recruitment is a step in Isconova’s further expansion, and increased involvement, in the area of human vaccines, concurrent with the Board of Directors’ decision to prepare the company for listing at Nasdaq OMX First North.

Uppsala Sweden August 24, 2009. Isconova AB, a Company developing producing and selling adjuvants for veterinary and human vaccines has appointed a new CEO, Lena Söderström, who will succeed Bengt Falk on 1 November 2009.

Two cornerstone patent applications covering Isconova’s most recent development of its adjuvant technology platform with improved safety and efficacy has been granted in Europe.